These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 320280)

  • 1. Prevention through immunization: new opportunities or end of the road?
    Krause RM
    J Infect Dis; 1977 Feb; 135(2):318-29. PubMed ID: 320280
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary immunization of infants and children with group A streptococcal M protein.
    Fox EN; Pachman LM; Wittner MK; Dorfman A
    Zentralbl Bakteriol Orig; 1970; 214(3):352-63. PubMed ID: 4926928
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of adjuvants in the production of group A streptococcal antiserum in rabbits.
    Prakash K; Lakshmy A; Sharma KB
    Indian J Med Res; 1982 Jul; 76():109-15. PubMed ID: 6757119
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.
    Baker CJ; Rench MA; Edwards MS; Carpenter RJ; Hays BM; Kasper DL
    N Engl J Med; 1988 Nov; 319(18):1180-5. PubMed ID: 3050524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic immunization with streptococcal immunoglobulin-binding protein Sib 35 induces protective immunity against group: a Streptococcus challenge in mice.
    Okamoto S; Tamura Y; Terao Y; Hamada S; Kawabata S
    Vaccine; 2005 Sep; 23(40):4852-9. PubMed ID: 15990202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Further study of the prevention of streptococcal infections in experiments on monkeys].
    Keller V; Dzhikidze EK; Voskanian NA; Kiunemund O; Knol' G
    Vestn Akad Med Nauk SSSR; 1986; (3):66-8. PubMed ID: 3518270
    [No Abstract]   [Full Text] [Related]  

  • 7. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection.
    Sabharwal H; Michon F; Nelson D; Dong W; Fuchs K; Manjarrez RC; Sarkar A; Uitz C; Viteri-Jackson A; Suarez RS; Blake M; Zabriskie JB
    J Infect Dis; 2006 Jan; 193(1):129-35. PubMed ID: 16323141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoid thyroiditis following immunization with group A streptococcal vaccine.
    Tonooka N; Leslie GA; Greer MA; Olson JC
    Am J Pathol; 1978 Sep; 92(3):681-90. PubMed ID: 356626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus.
    Chen X; Li N; Bi S; Wang X; Wang B
    PLoS One; 2016; 11(12):e0168861. PubMed ID: 28030629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reactivity of rabbits in chronic streptococcal infection].
    Toshkov A; Zhelev V; Shirova L; Obretenova K; Radeva M
    Izv Mikrobiol Inst (Sofiia); 1970; 21():131-41. PubMed ID: 4948932
    [No Abstract]   [Full Text] [Related]  

  • 11. Primary immunization of infants and children with group A streptococcal M protein.
    Fox EN; Pachman LM; Wittner MK; Dorfman A
    J Infect Dis; 1969 Nov; 120(5):598-604. PubMed ID: 5346538
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors that enhance the potency of streptococcal group-specific antisera.
    Greenblatt JJ; Eichmann K; Braun D; Krause RM
    J Infect Dis; 1971 Oct; 124(4):387-93. PubMed ID: 5143845
    [No Abstract]   [Full Text] [Related]  

  • 13. Group A streptococcus vaccine may be ready for phase I clinical trials in late 1989.
    Raymond CA
    JAMA; 1988 Nov; 260(19):2778. PubMed ID: 3054182
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
    [No Abstract]   [Full Text] [Related]  

  • 15. The eradication of gonorrhea through immunization with specific antigens.
    Casper WA
    Int J Dermatol; 1974; 13(1):29-31. PubMed ID: 4591731
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
    Mansour NM; Abdelaziz SA
    Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of neonatal group B streptococcal infections: advances in maternal vaccine development.
    Coleman RT; Sherer DM; Maniscalco WM
    Obstet Gynecol; 1992 Aug; 80(2):301-9. PubMed ID: 1635750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity in animals and man of a structurally defined polypeptide of streptococcal M protein.
    Beachey EH; Stollerman GH; Johnson RH; Bisno AL; Ofek I
    Trans Assoc Am Physicians; 1979; 92():346-54. PubMed ID: 398625
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy.
    Pandey M; Sekuloski S; Batzloff MR
    Immunol Cell Biol; 2009 Jul; 87(5):391-9. PubMed ID: 19417770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resurgence of severe streptococcal diseases: prospects for a streptococcal vaccine.
    Markowitz M
    Int J Tissue React; 1993; 15(3):105-7. PubMed ID: 8188446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.